Research progress in the mechanism of antibody-drug conjugate and its application in the treatment of bladder cancer / 现代泌尿外科杂志
Journal of Modern Urology
; (12): 459-463, 2023.
Article
de Zh
| WPRIM
| ID: wpr-1006039
Bibliothèque responsable:
WPRO
ABSTRACT
Bladder cancer (BC) is one of the most common malignancies of the urinary tract. Surgery combined with chemoradiotherapy is the mainstay of treatment, but BC is markedly heterogeneous, leading to unsatisfactory outcomes. Antibody-drug conjugate (ADC), a new type of targeted drug, has achieved remarkable results in the treatment of tumors by coupling a chemical junction with a highly cytotoxic small molecule, which can exert anti-tumor effects while avoiding the impacts on normal cells. To date, several ADCs have been used in the treatment of BC at home and abroad, and play an increasingly important role in the field of BC therapy. This article briefly introduces the mechanism of ADC, the current application of ADC in BC treatment, and the problems and challenges faced, hoping to provide reference for clinical work.
Texte intégral:
1
Indice:
WPRIM
langue:
Zh
Texte intégral:
Journal of Modern Urology
Année:
2023
Type:
Article